BioMed Research International

BioMed Research International / 2017 / Article
Special Issue

Basic and Translational Advances in Glioblastoma

View this Special Issue

Review Article | Open Access

Volume 2017 |Article ID 8139848 |

Moon Nyeo Park, Hyo Sook Song, Myungsun Kim, Min-Jung Lee, Whisung Cho, Hyun-Jin Lee, Cho-Hyun Hwang, Soojong Kim, Yechae Hwang, Beomku Kang, Bonglee Kim, "Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs", BioMed Research International, vol. 2017, Article ID 8139848, 24 pages, 2017.

Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs

Academic Editor: Francesco Pasqualetti
Received04 May 2017
Revised17 Aug 2017
Accepted17 Sep 2017
Published18 Oct 2017


Common care for glioblastoma multiforme (GBM) is a surgical resection followed by radiotherapy and temozolomide- (TMZ-) based chemotherapy. Unfortunately, these therapies remain inadequate involving severe mortality and recurrence. Recently, new approaches discovering combinations of multiple inhibitors have been proposed along with the identification of key driver mutations that are specific to each patient. To date, this approach is still limited by the lack of effective therapy. Hopefully, novel compounds derived from natural products are suggested as potential solutions. Inhibitory effects of natural products on angiogenesis and metastasis and cancer suppressive effect of altering miRNA expression are provident discoveries. Angelica sinensis accelerates apoptosis by their key substances influencing factors of apoptosis pathways. Brazilin displays antitumor features by making influence on reactive oxygen species (ROS) intensity. Sargassum serratifolium, flavonoids, and so on have antimetastasis effect. Ficus carica controls miRNA that inhibits translation of certain secretory pathway proteins during the UPR. Serratia marcescens and patupilone (EPO 906) are physically assessed materials through clinical trials related to GBM progression. Consequently, our review puts emphasis on the potential of natural products in GBM treatment by regulating multiple malignant cancer-related pathway solving pending problem such as reducing toxicity and side effect.

1. Introduction

Glioblastoma (GBM) is the most common and malignant CNS (central nervous system) tumor originating from glial cells [1]. It is one of the most lethal types of brain tumor [2]. During the past 30 years, the therapies for this dreadful disease were researched [3]. The most standard care for GBM is surgical resection followed by radiotherapy and temozolomide- (TMZ-) based chemotherapy [4]. Although the standard treatments for glioblastoma have been introduced, the mean survival period of GBM still remains short, ranging from only 12 to 15 months, and the 5-year survival rate is only 4-5%, indicating that contemporary treatments are not as effective in treating glioblastoma [2, 5].

There are mainly two reasons behind the limitations on treating glioblastoma. Firstly, various factors in the pathology of glioblastoma deter current chemotherapies from being fully effective. For example, the highly vascularized network of GBM leads to resistance from conventional chemotherapy. Also, the blood-brain barrier (BBB) makes it difficult to deliver the drug to the cancer, resulting in recurrence without full recovery [6].

Secondly, the drugs used in current chemotherapy of GBM have certain limitations. The limitations include side effects and poor effectiveness. TMZ is observed to have severe side effects, such as myelosuppression [7] and cerebral edema [8]. Also, TMZ showed poor improvement in survival periods (increased survival only for about 2 months) in patients who received treatment with TMZ combined with radiation and tumor resection. Furthermore, since patients die from recurrent tumors, chemoresistance is also a problem [9].

Bevacizumab, which was especially approved in United States, also exhibits adverse events, such as interference in normal blood flow and occurrence of coronary artery disease and peripheral artery disease. Other severe side effects include gastrointestinal perforation, bleeding, allergic reactions, blood clots, and an increased risk of infection [10]. Moreover, some say that the addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective [11].

The limitations of current chemotherapy necessitate the need for novel drugs that can be more effectual, induce less side effects, and bring a favorable prognosis. Already, natural products express various potentials, such as enhanced bioavailability and increased stability when forming interaction between active constituents [12]. Also, especially in cancer treatment, traditional oriental herbal medicine is used by patients to improve immunity, since natural killer (NK) cells are activated when drugs are admitted. This leads to inhibition of tumor development and progression, helping the survival of cancer patients [13].

Consequently, we collected recent papers including efficacy for GBM treatment on the grounds of angiogenesis, metastasis, apoptosis, ER stress, ROS, MDR, and miRNA through increased stability, protection from toxicity, enhanced pharmacological activity, improved tissue macrophage distribution, and protection from physical and chemical degradation.

The purpose of this review exhibits scientific accuracy and quality compared to traditional data that is to summarize and organize by standardization, efficacy mechanism, and justification of pharmacokinetic and pharmacological parameter [1418].

2. Apoptotic Effect of Natural Products

Apoptosis is a well-organized programmed cell death, which is induced by various natural products (Table 1) [19]. The methanol extract of Angelica sinensis (AS-M) is commonly used in natural product to treat several diseases. AS-M activates both p53-dependent and caspase-independent pathways for apoptosis by inducing cell cycle arrest [20]. Hyperforin (HP), polyphenolic procyanidin B2 (PB-2), and hypericin (HY) are extracts of Hypericum perforatum L. (H. perforatum). HP causes cell death by apoptosis involving a caspase-dependent pathway. PB-2 triggers cytostatic and apoptotic activities in LN229 [21]. Angelica sinensis has been observed to have biological activities in traditional Chinese medicines. Cell cycle arrest and apoptosis of AS-C induce anticancer effects in GBM. n-Butylidenephthalide (BP) is isolated from the chloroform extract of Angelica sinensis. It is a naturally occurring compound, triggering cell cycle arrest and apoptosis in malignant brain cancer. BP has antitumoral activity in GBM cells via mitochondria-dependent apoptosis and PKC signaling which associates upregulation Nur77 [22]. Flavonoid-rich fraction 6 (Fr6) and proanthocyanidins (PAC) fraction are isolated from cranberry presscake and whole cranberry. They have potent anticancer effects, such as inducing cell cycle arrest and apoptosis [23]. TCE, which is a methanol extract of Tinospora cordifolia, significantly showed increase of GFAP expression and differentiation in C6 glioma cells [24]. Thymoquinone (TQ), a compound isolated from Nigella sativa seed oil, has autophagic activity via mediating lysosomal membrane permeabilization, as well as caspase-independent apoptotic cell death [25]. Niclosamide is one of the 160 synthetic and natural toxic substances. It inhibits NOTCH-, mTOR-, and NF-kB signaling cascades of pGBM cells [26]. Brazilin, one of the compounds in Caesalpinia sappan, enhanced apoptosis in glioma cells with an increase of the ratio of cleaved PARP and a decrease of the expression of caspase-3 and caspase-7 [27]. Δ(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two main cannabinoids contained in marijuana. THC- and CBD-loaded microparticles showed enhanced apoptosis and reduction of cell proliferation and angiogenesis in mice bearing glioma xenografts [28]. Two resveratrol oligomers, hopeaphenol and r2-viniferin, showed antiproliferative effect in D-GBM cells by inducing caspase-9 and caspase-3/7 activation [29]. wogonin is one of the main compounds of Scutellaria baicalensis, which trigger growth arrest as well as apoptosis by generating reactive oxygen species in human glioma cells. It is also shown that wogonin affects DNA damage, p53 regulation, and the suppression of protein synthesis [30]. Both curcumin and chokeberry extract reduce MMP gene expression in order to inhibit invasion and induce apoptosis [31]. Zeng Sheng Ping (ZSP, also known as ACAPHA and antitumor B) is a composition of 6 traditional Chinese herb used in numerous cancers. It also has an effect on medulloblastoma and glioblastoma, inhibiting Notch signaling and reducing expression of stem cell markers [32]. Andrographolide, a compound isolated from Andrographis paniculata, inhibits PI3K/AKT signaling pathway and arrests the G2/M phase, to mediate cell proliferation [33]. 3-Deoxyschweinfurthin B (3dSB) and 3-deoxyschweinfurthin B-like p-nitro-bis-stilbene (3dSB-PNBS) are two similar compound which mimics schweinfurthin activity. They induce PARP cleavage and eIF2 phosphorylation and show increase of GRP78 and PDI expression [34]. Jaceosidin, which is isolated from the Chinese herb Artemisia argyi, leads glioblastoma cells to apoptosis in the G2/M phase via mitochondrial-caspase-3-dependent pathway [35]. Resveratrol, a natural compound well-known for autophagic activity, develops U87 glioma cells into autophagosome and arrests the cell cycle in S-G2/M phase, although not being related to its cytotoxicity [36]. Tagitinin C, which is isolated from Tithonia diversifolia methanolic extract, increases PARP, p-p38, ULK1, and LC3-II expression to autophagy interplay with apoptosis in glioblastoma [37]. 2 (Z)-N-(2-(Dimethylamino)ethyl)-2-(3-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)phenoxy) acetamide (PCH4) is a derivative of n-butylidenephthalide (BP). It mediates the JNK pathway and decreases Nur77 expression [38]. γ-Mangostin, a compound of Garcinia mangostana, showed apoptotic activity by ROS production, leading to cell damage and ROS-dependent mitochondrial dysfunction [39]. Inositol hexaphosphate (IP6) is a phytochemical, found in corns, cereals, nuts, and high-fiber content foods. IP6 has apoptotic effects that upregulates calpain and caspase-3 activities and downregulates the survival factors BIRC-2 and telomerase in T98G cells [40]. Methyl gallate isolated from Spondias pinnata activates ERK1/2 which results in apoptosis [41]. Water extract of Ruta graveolens L., commonly known as rue, induces death in different glioblastoma cell lines. Its effects were mediated by ERK1/2 and AKT activation and the inhibition of the pathways, PD98058 and wortmannin, reverting its antiproliferative activity [42]. Oridonin, a natural diterpenoid compound isolated from the traditional Chinese medicine, Rabdosia rubescens, induced U87MG glioma cell apoptosis and RNA accumulation in nucleus at 12 h-time point. Before U87MG cell apoptosis, the RanGAP1 protein amount decreased and RanGTP accumulated in nucleus [43]. Deoxypodophyllotoxin (DPT) is a semisynthetic compound derived from the extract of Dysosma versipellis (Hance) M.Cheng. G2/M phase arrest by DPT results in cell death. However, DPT failed to downregulate these cell cycle regulatory molecules in SF126 glioblastoma cells and stopped the cell cycle at M phase [44]. Ardipusilloside I (ADS-I) is a natural compound that can be isolated from Ardisia pusilla A.DC. It was incorporated into polymer microspheres. ADS-I wafers’ biodegradable implants against glioblastoma are associated with a decrease in vascular endothelial growth factor, C-reactive protein, tumor necrosis factor-α and interleukin-6, and an increase in interleukin-2 expression [45]. Supercritical CO2 extract of mango ginger (Curcuma amada Roxb.) demonstrates anticancer activity in the U-87MG human glioblastoma cell line directly or in synergistic combination with conventional chemotherapeutic drugs. This is related to downregulating the mRNA expression of genes such as STAT3, Bcl-2, and p53 and increases the Bax/Bcl-2 ratio [46]. Curcumin, combined with temozolomide, showed synergy in inhibiting growth of glioblastoma cell line [47]. Hedyotis diffusa Willd extract inhibits the growth of human glioblastoma cells by inducing mitochondrial apoptosis via AKT/ERK pathways [48]. Icariin and temozolomide demonstrate synergistic anticancer effects in glioblastoma. Icariin inhibited proliferation, induced apoptosis, prevented migration and invasion in U87MG cells, demonstrating the antitumor activities of icariin against GBM [49]. Hispidulin is a naturally occurring flavonoid, which can be extracted from Saussurea involucrata Kar. It enhances the antitumor effects of temozolomide in glioblastoma by activating AMPK [50]. Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression. OLE exhibited apoptosis and necrosis in the GBM cell lines and significantly induced the expression of miR-153, miR-145, and miR-137 and decreased the expression of the target genes of these miRNAs in GSCs [51]. Ficus carica Latex extract prevents invasion through induction of let-7d expression in GBM cell lines. FCL causes cell death in GBM cells with different responses to TMZ and this effect is synergistically increased in combination with TMZ [52]. Honokiol, a natural bioactive molecular compound isolated from the Magnolia officinalis, downregulates STAT3 and activates MAPK, which are involved in the induction of apoptosis in glioblastoma cell line U87. HNK increased expression of Bax and decreased expression of Bcl-2, resulting in downregulation of Bcl-2/Bax ratio and confirming that the intrinsic apoptotic pathway is also involved in HNK-induced apoptosis in U87 cells [53].

Family namesMedical plantsCompounds/extractsDose/durationTarget molecules and additional efficacyCell linesReferences

HypericaceaeHypericum perforatum L. (H. perforatum)Hyperforin (HP), polyphenolic procyanidin B2 (PB-2), hypericin (HY)HP 20 µM for 24 h
PB-2 80 µM for 24 h
(Annexin V-binding analysis)
Annexin V positive cellsLN229[21]

ApiaceaeAngelica sinensisn-Butylidenephthalide (BP)75 µg/mL for 6, 12, 24 h (cell cycle analysis)
75 µg/mL for 24, 48, 72 h (Cell Death Detection Kit, POD)
75 µg/mL for 0, 1.5, 3, 6, 12, 24, 48 h (Western blot analysis)
DBTRG-05MG, DBTRG 8401 (human)
↑p53, p16, Bax, AIF protein induce Fas expression, caspase-8 (dose-dependent), procaspase-9, procaspase-3
↓cdk2, cdk4, cdk6, cyclin D1, cyclin E,
RG2 (rat)
↑p27, Bax, AIF induce Fas expression, caspase-8 (maximum expression at 24 h), procaspase-9, procaspase-3
↓cdk2, cdk4, cdk6, cyclin D1, cyclin E, p21
cell cycle arrest (G0-G1 phase)
DBTRG-05MG, GBM 8401 (human), RG2 (rat)[22]

EricaceaeVaccinium macrocarpon (cranberry)Flavonoid-rich fraction 6 (Fr6), proanthocyanidins (PAC) fractionFr6 concentration: 0, 50, 100, 150, 200, 250, 300 mg/L for 24 and 48 h (cell cycle distribution analysis) (Annexin V, PI)
PAC concentration: 0, 20, 40, 60, 80, 100, 120, 140, 160 mg/L for 24, 48 h (cell cycle distribution analysis) (Annexin V, PI)
↑G1 phase
↓S phase
cell cycle arrest (G1 phase)

MenispermaceaeTinospora cordifoliaEthanol extract250 μg/ml, 350 μg/ml for 72 h↑GFAP, NCAM,
↓MMP-2,9, cyclin D1, Bcl-xl
C6, U87 MG[24]

RanunculaceaeNigella sativaThymoquinone20 μM, 40 μM for 24 h↑p62, cathepsin BT98G, U87 MG[25]

Niclosamide1.5 μm/L for 48 h↓WNT/CTNNB1-, NOTCH-, mTOR-, NF-kBLN229, T98G, U87MG, U138, and U373 MG[26]

FabaceaeCaesalpinia sappanBrazilin10 μg/ml, 15 μg/ml, 20 μg/ml for 24 h↑PARP
↓caspase-3, caspase-7
U87 MG[27]

CannabaceaeMarijuana (cannabis)Δ(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD)75 mg MPs (biodegradable polymeric microparticles) every 5 days↓KI67, CD31U87 MG[28]

Hopeaphenol, r2-viniferin20 μg/ml (hopeaphenol), 100 μg/ml (r2-viniferin) for 120 h↓caspase-9, caspase-3/7D-GBM[29]

LamiaceaeScutellaria baicalensisWogonin0–100 μM
for 24 h
↑ AMPK, p53
↓mTOR, 4E-BP1
G0/G1 phase arrest
U87 MG, U343 MG, U373 MG, T98G, MCF-10A[30]

RosaceaeAronia melanocarpaChokeberry extract, curcumin10 μg/ml (curcumin), 50 μg/ml (polyphenolics from Aronia melanocarpa)↓MMP-2, -14, -16, -17U373 MG[31]

(1) Fabaceae
(2) Polygonaceae
(3) Lamiaceae
(4) Asteraceae
(5) Rutaceae
(6) Dioscoreaceae
(1) Sophora tonkinensis
(2) Polygonum bistorta
(3) Prunella vulgaris
(4) Sonchus brachyotus
(5) Dictamnus dasycarpus
(6) Dioscorea bulbifera
ZSP (Zeng Sheng Ping)0, 50, 100 mg/kg/day↓notch 2, Hes1, CD133U87 MG, HSR-GBM1 JHH-GBM10, JHH-GBM14[32]

AcanthaceaeAndrographis paniculataAndrographolide10 μM↓PI3K/AKT, caspase-3
G2/M phase arrest
U251, U87 MG[33]

Macaranga schweinfurthii3-Deoxyschweinfurthin B (3dSB), 3-deoxyschweinfurthin B-like p-nitro-bis-stilbene (3dSB-PNBS)3dSB (500 nM), 3dSB-PNBS (500 nM), DMP-PNBS (1 M), or Y-27632 (10 M) for 48 h↑PARP, GRP78, PDI

AsteraceaeArtemisia argyiJaceosidin100 μM/L for 24 h↑p53, Bax, cytochrome c, caspase-3
G2/M phase arrest
U87 MG[35]

Resveratrol30 μM for 48 h↑ Atg5, beclin-1, LC3-II, PI3k class III
↓CD133, OCT4, mTor/AKT/p70S6K
S-G2/M phase arrest
U-87 MG, U-251, U-138 MG[36]

AsteraceaeTithonia diversifoliaTagitinin C10 μg/mL for 12 h↑PARP, p-p38, ULK1, LC3-IIU373 MG[37]

ApiaceaeAngelicasinensis(Z)-N-(2-(Dimethylamino)ethyl)-2-(3-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)phenoxy)acetamide (PCH4)50 µg/ml for 24 h↓Nur77, JNKDBTRG-05MG, GBM 8401[38]

ClusiaceaeGarcinia mangostanaγ-Mangostin80 μM for 8 h↑NK cell, ROS
↓PGE2, COX-2, NO
U87 MG, GBM 8401[39]

High-fiber foods (such as corns, cereals, legumes, nuts, oil seed, soybean)Inositol hexaphosphate (IP6)0.5, 1 mM for 24 h↑Bax, Bax: Bcl-2 ratio, cytosolic level of cytochrome c, Smac/Diablo (in the cytosol), 80 kD calpain, caspase-9, 85 kD PARP fragment
↓cytochrome c, Smac/Diablo, Bcl-2, BIRC-2, hTERT

AnacardiaceaeSpondiaspinnataMethyl gallate1 to 30 μg/ml for 48 hERK1/2 activation, apoptosisU87MG[41]

RutaceaeRutagraveolens L.R. graveolens a.e.1 mg/ml for 24, 48, 72 hoursERK1/2, AKT activation, apoptosis in A1 mes-c-myc cellsU87MG, C6, U138[42]

LamiaceaeRabdosiarubescensOridonin5 μM for 12 h↓RNA transferation, RanGTPU87MG[43]

BerberidaceaeDysosmaversipellisDeoxypodophyllotoxin (DPT)30 nM for 72 h↓Cdc2, cyclin B1, Cdc25cU87MG, SF126[44]

PrimulaceaeArdisiapusilla A.DCArdipusilloside I (ADS-I)(20 μL, 5 mg/mL) for 4 h↓vascular endothelial growth factor, C-reactive protein, tumor necrosis factor-α, interleukin-6, interleukin-2rat C6 glioma cells (in vivo)[45]

CurcumaCurcumaamada Roxb.Supercritical CO2 extract of mango ginger (CA)0–100 mg/mL for 48 h↓STAT3, Bcl-2, mutant p53 expression
↑ratio of Bax/Bcl-2

Curcumin, temozolomide7.5 μM for 72 h↓phosphorylation of cyclin B1, cyclin D1
G2/M arrest
C6, U251MG

RubiaceaeHedyotisdiffusa WilldHDW extract0, 4, 8 mg/ml for 24 h↓Bcl-2/Bax ratio, AKT suppression ↑caspase-3, Bcl-2, Bax and ERK
S/G2-M phase arrest, MMP collapse

BerberidaceaeEpimediiherbaIcariin0, 5, 10, 20 μM for 2 h↓NF-kB, piwil4, Rac1
vasodilator-stimulated phosphoprotein (VASP)

Hispidulin10 μM for 2 h↓Bcl2
G2 cell cycle arrest
Human GBM

OleaceaeOleaeuropaeaOlea europaea leaf extract (OLE)1 mg/ml, 2 mg/ml for 24 h↑ miR-153, miR-145, miR-137T98G,

MoraceaeFicuscarica LatexFCL extract0.125 mg/ml for 24 and 48 h↓HMGA2, VEGFA ↑HMGA2, VEGFAT98G,
U-138 MG,
U-87 MG

MagnoliaceaeMagnoliaofficinalisHonokiol10, 20 µg/ml for 12 or 24 h↓STAT3 signaling, ERK1/2,
↑p38 MAPK signaling pathway
G0/G1 phase cell cycle arrest
U87MG, U251,

Apocynaceae/ZingiberaceaeRhazyastricta, ZingiberofficinaleCrude alkaloid (CAERS), flavonoid (CFEZO)10 µg/mL/for 24, 48, 72 h↓nuclear NF-kB, p65, survivin, XIAP, cyclin-D1,
↑mitochondrial cytochrome c, Bax : Bcl-2 ratio, activities of caspase-3 and -9, and PARP-1 cleavage, p53, p21, Noxa

PrimulaceaeArdisiapusilla A.DCArdipusilloside I20 µg/mL for 24 h↑Beclin 1, LC3
arrest at G2/M phase
U373, T98G[55]

BerberidaceaeBerberisamurensisBerbamine derivative, BBMD31 µg/mL/24 h or 48 h↑miRNA-4284, JNK/AP-1 signaling, caspase-3 and cleavage of poly (ADP-ribose) polymerase (PARP) microRNA-4284 (miR-4284), phosphorylation of the cJun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK)Cancer stem-like cells (CSCs) from four GBM patients (PBT003, PBT008, PBT022, and PBT030)[56]

SolanaceaeWithaferin A (WA)0.025–3 μM for 72 h↓G2/M cell cycle arrest, phosphorylation of AKT, mTOR, p70 S6K, c-Met, EGFR, Her2U87MG, U251, T98G[57]

AmaryllidaceaeSternbergialuteaLycorine↓actin, CYP3A4 cytostatic effectB16F10 melanoma (mice)[58]

Lavandin, peppermint, spearmint, sage, cherries, cranberries, Perilla (Perillafrutescens), lemongrass, wild bergamot, gingergrass, savin, caraway, celery seeds//lemonPerillyl alcohol (monoterpene alcohol) //Perillyl alcohol: ↑TGF-β
Limonene: ↓isoprenylation, coenzyme Q synthesis

ApiaceaeAngelica sinensisMethanol extract of Angelicasinensis100 µL for 72 h↑p16 and p53, CDK inhibitors
cell cycle arrest at the G0-G1 phase
DBTRG-05MG, BALB/3T3 [20]

4,6-Dichloro-5-aminopyrimidineThiazolo5,4-d pyrimidines48 hT98G[60]

ApiaceaeBupleurum scorzonerifolium (Nan-Chai-Hu)IsochaihulactoneNo concentration (all cell ER stress Western)
80 μM for 0, 24, 48 h (cell cycle)
20, 40, 80 μM for 24 h (Annexin V-PI double stain)
50, 200 mg/kg daily for 30 d (in vivo)
↑DDIT3, NAG-1, PARP, caspase-3/9/7
↓pERK, Bcl-2
cell cycle arrest G2/M phase, subG1 population increase (naturally pERK induce DDIT3. But DDIT3 increased with low pERK. There is new pathway to increase DDIT3)
GBM cell lines
8401, 8901, U87MG, G2T, 131TXM, 1XM, RG2, GL261
(each cell for ER stress Western, 2 cells for cell cycle)

SolanaceaeLycium chinense (Lycii radicis [Cortex])Kukoamine A0, 5, 10, 20 μM for 48 h (cell cycle)
40, 60, 80 μM for 48 h on U251; 10, 20, 30 μM for 48 h on WJ1 (Annexin V-PI double stain, cell activation observed, Western)
↑Bax, caspase-3, E-cadherin
↓5-Lipoxygenase (5-LOX), Bcl-2, CCAAT/enhancer binding protein β (C/EBPβ), N-cadherin, vimentin, twist and snail+slug
Proliferation, colony formation, migration, invasion, growth of tumors all decreased, cell cycle arrested G0/G1 phase, less cell cycle S phase, less cytotoxic for C6
Human GBM cells U251 & WJ1,
rat glioma cells (C6)

ValerianaceaeNardostachys jatamansi [Rhizome]N/A0, 20, 40, 60, 80 µg/mL for 24, 48, 72 h (cell counting, AO/EB Dual Fluorescence Staining)
0, 20, 40, 60, 80 µg/mL for 24 h (cell cycle analyses)
0, 20, 40, 60, 80 µg/mL for 1 week (clonogenic assay)
10–70 µg/mL for 24 h (DNA Fragmentation)
No concentration measured for 24 h (Western immunoblotting)
↓caspase-3/9, PARP
cell shrinkage, membrane blebbing, echinoid processes, pyknosis, myorrhexis, low density (~40 µg/mL) early apoptosis, high density (60 µg/mL) late apoptosis, G0/G1 arrest 60, 80 µg/mL
U87M (every experiment), U373MG[63]

N/AN/AMyricetin200 μM for continuous time (over 90 h) (real-time cell analyser instrument)
25, 50, 100, 200 μM for 24 h (Western)
↑Bax, cleaved caspase-3, caspase-9, Bad
↓cytochrome c, Bcl-2, MDM2, K-Ras, Raf-1, ERK, pERK
DBTRG-05MG, U251, U87MG
(DBTRG-05MG for every experiment, 3 cells for real-time cell viability)

LamiaceaeMelissa officinalisRosmarinic acid (RA) // luteolin-7-glucoside, caffeic acid, rosmarinic acid, protocatechuic acid, caftaric acid, ferulic acid, cichoric acid, Dulbecco’s modified Eagle’s medium (DMEM), Ampliflu Red, 2′,7′-Dichlorofluorescin diacetate (DCFH2-DA), 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), HPLC grade acetonitrile, trifluoroacetic acid (TFA)0, 50, 100, 140, 170, 200, 250, 300, 400 μM for 24, 48 h (RA cell viability)
0, 50, 100, 140, 170, 200 μM for 24, 48 h (N1 cell viability)
0, 10, 25, 40, 50, 75, 100 μM for 24, 48 h (N2, N3 cell viability)
(highest density is 0% survive)
↑intracellular reactive species (RS) (high density)
↓intracellular reactive species (RS) (low density)
cell proliferation decrease, at low density cell viability increase, at middle density apoptosis & antioxidant effect, at high density prooxidant effect & necrosis
RA < Aqueous < Ethanolic 40% < Ethanolic 70% (effect)
(pure RA, aqueous (N1), ethanolic 40% (N2), ethanolic 70% (N3), 4 kinds compared)
C6 rat glioblastoma[65]

temozolomide (TMZ)
0, 2, 4, 6, 8, 10 μM for 48 h (cell viability)
0, 2, 4, 6, 8, 10 μM β-escin + 0, 2, 4, 6, 8, 10, 50, 100 μM TMZ for 48 h (β-escin, TMZ combined cell viability)
No measurement of concentration for 24 h (Western only PARP-1)
↑cleaved PARP-1
synergy with TMZ
(Patient-derived) glioblastoma-initiating cells (GIC), U87MG[66]

AraceaeAcori graminei [Rhizoma]N/A0, 50, 100 μg/mL for 48 h on A172; 0, 100, 200 μg/mL for 48 h on U251 (Annexin V-PI double stain)
0, 25, 50, 100 μg/mL for 48 h on A172; 0, 50, 100, 200 μg/mL for 48 h on U251 (Western)
↑Bax, cleaved caspase-3/8/9, mTOR (A172 only), LC3II/I, atg5, beclin-1, p-AMPK (both)
↓Bcl-2, p-p70S6K, p-mTOR (A172 only), p62 (both)
Etop inhibition pathway is contrasted with each experiments dependent/independent confirm
A172, U87MG, U251, U118,
4 cell MTT (all experiments)

AraliaceaePanax ginsengGinsenoside Rg3 
temozolomide (TMZ)
10, 20, 40, 80, 120, 180 μg/mL TMZ or RG3 for 24, 48, 72, 96, 120, 144 h; 10, 80, 180 μg/mL TMZ&RG3 1 : 1 for 24, 48, 72, 96, 120, 144 h (proliferation inhibition)↓VEGF
Synergy with TMZ
Primary human umbilical vein endothelial cells (HUVECs), rat C6 glioma cell[68]

LamiaceaeZataria multifloraThymol, carvacrol0, 25, 50, 100, 150, 200 μg/ml for 2 h and 0, 3, 6 Gy Ionizing radiation (IR). After IR incubated for 48 h in fresh medium (MTT)ZM treatment strengthen IR antiproliferationA172[69]

BoraginaceaeLithospermumShikonin2.5, 5, 7.5 μmol/L for 0, 12, 24, 36, 48, 72 h (Cell proliferation)
0, 2.5, 5, and 7.5 μmol/L for 0, 24, 48 h (scratch wound-healing assays)
2.5, 5, 7.5 μmol/L for 48 h (Western)
↑p-β-catenin Y333 (U251 only)
↓MMP-2, MMP-9, p-AKT, p-PI3K (both), p-β-catenin Y333 (U87 only)
scratch wound-healing assay: higher density shikonin less regrowth
U87MG, U251[70]

ZingiberaceaeCurcuma longaCurcumin (diferuloylmethane)
temozolomide (TMZ)
20, 50, 100 μM curcumin for 72 h
100, 300, 500 μM TMZ for 72 h (MTT)
Synergy with TMZ

Taiwanese propolis (Erhmei (in central Taiwan), Fangliao (in southern Taiwan))Prenylflavanone (propolin G), Taiwanese propolis (TP)0, 2.5, 5, 10 µg/mL/72 h (cell cycle analysis). 7.5 µg/mL/24 h (morphological analysis of apoptotic cells). 12.5 µg/mL/0, 4, 5, 6, 7 h (activity of caspase. Rat C6 glioma). 0, 2.5, 5, 7.5, 10 µg/mL/48 h (Western blotting assay). 2.5, 5, 10, 20, 40 µM with 1.0 mL of 0.3 mM DPPH in methanol (DPPH free radical scavenging activity)↑sub-G1 cell population, caspase-3, caspase-8, caspase-9, cleavage form of PARP (85 kDa), p21waf1, ↓ procaspase-3, procaspase-8, procaspase-9, Bid, cyclin B1, cyclin D1, EC50 (20.5 µM)/caspase-dependent signal pathway, mitochondrial-dependent pathway, modulation of cell cycle regulators’ gene expression, ROSrat C6 glioma, DBTRG-05MG (human)[71]

Curcumin20 µmol/L/12, 24 h (cell cycle analysis). 0, 5, 10, 15, 20, 25 µmol/L/2 h (Western blot). 20 µmol/L/0, 0.25, 0.5, 1, 2, 4, 6, 12, 24, 48 h (Western blot). 20 µmol/L/0, 15, 30, 60, 120 min (Western blot). 20 µmol/L/0, 5, 15, 30, 60 min (Western blot)↑G1 phase, p21, Egr-1, phosphorylated ERK1/2, JNK1/2, p38, phosphorylated Elk-1, ↓S phase, G2-M phase, cyclin D1/cell cycle arrest (G1 phase), ERK and JNK MAPK/Elk-1/Egr-1 signal cascade (p53-independent transcriptional activation of p21Waf1/Cip1)U-87MG[47]

RanunculaceaeCoptischinensis, HydrastiscanadensisBerberine50, 75, 100, 150 µg/ml/48 h (cell cycle analysis). 0, 50, 100, 150, 200 µg/ml/24 h (Western blot, caspase-3 colorimetric protease assay)↑G1 phase, p27, Bax, caspase-9, caspase-3, PARP, ↓G2/M phase, S phase, CDK2, CDK4, cyclin D, cyclin E, Bcl-2 family, procaspase-9/cell cycle arrest (G1 phase), apoptosis (disruption of the mitochondrial membrane potential, activation of caspase pathways)T98G[72]

Hypericum polyanthemumThree benzopyrans (6-isobutyryl-5,7-dimethoxy-2,2-dimethyl-benzopyran (1), 7-hydroxy-6-isobutyryl-5-methoxy-2,2-dimethyl benzopyran (2), 5-hydroxy-6-isobutyryl-7-methoxy-2,2-dimethyl-benzopyran (3))10 µg/ml/96 h (cell cycle analysis)↑% sub-G1/cell cycle arrest (G2/M phase)U-373MG[74]

Crude extracts from Rhazya stricta and Zingiber officinale affect growth and proliferation of GBMs. Apoptosis induction was mediated by release of mitochondrial cytochrome c, increased Bax : Bcl-2 ratio, enhanced activities of caspase-3 and caspase-9, and PARP-1 cleavage [54]. Ardipusilloside I, a triterpenoid saponin isolated from Ardisia pusilla A.DC, significantly inhibited proliferation of both U373 and T98G glioma cells. The cytotoxic activity of ADS-I is associated with the induction of G2/M arrest and cell apoptosis [55]. Berbamine derivative (BBMD3) inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via upregulation of miRNA-4284 and JNK/AP-1 signaling. BBMD3 also increased phosphorylation of the cJun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), resulting in increased expression of phosphorylated cJun and total c-Fos [56]. Withaferin A, an oxidative cytotoxic agent, resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through AKT/mTOR pathway inhibitory modulation [57]. Lycorine, C1, C2-ether derivatives of Sternbergia lutea, downregulates activity of highly lipophilic analogues against cancer cells. The derivatization of C1- or C2-hydroxyls as methyl ethers causes a complete loss of activity [58]. Perillyl alcohol (monoterpene alcohol) and limonene, respectively, play an important role in cancer therapy. Both can inhibit tumor progression through downregulation of basal production of VEGF in cancer cells. They also suppress the mevalonate pathway and isoprenylation of small G proteins, leading to tumor regression [59]. The methanol extract of Angelica sinensis induces cell apoptosis and suppresses tumor growth in human malignant brain tumors. The AS-M mechanism was found to involve the cyclin/CDK/CKI cell cycle regulatory system and the upregulation of p16 and p53 expression [20]. Thiazolo (5,4-d) pyrimidines displayed significant antiproliferative activity, particularly in leukemia and lung adenocarcinoma cells [60]. Chinese traditional herb Nan-Chai-Hu, the root of Bupleurum scorzonerifoliu, has isochaihulactone. Isochaihulactone-induced DDIT3 caused apoptosis by stimulating pERK-independent apoptosis. Used with isochaihulactone in GBM cell lines, it can cause ER homeostasis disruption by increasing inducing DNA damage inducible transcript 3 (DDIT3) and NAG-1 expression. PARP and caspase-3/9/7 are also increased, and Bcl-2 is decreased. The cell cycle arrested at G2/M phase and showed increased apoptosis. DDIT3 expression was independent of 78 kDa glucose-regulated protein (GRP78) and protein kinase RNA-like endoplasmic reticulum kinase (pERK) expression. In in vivo studies, tumor growth was suppressed. Also, in the xenograft model, DDIT3 and caspase-3 overexpression, not pERK expression, were observed in the xenograft model [61]. Cortex lycii radicis is the dried root bark of Lycium chinense. Growth inhibition effect on GBM cells was observed from crude extract of Cortex lycii radicis. Kukoamine A (KuA) is a spermine alkaloid derived from it. KuA treatment suppressed proliferation, colony formation, growth of tumors, migration, and invasion of GBM cells. KuA increases apoptotic proteins, Bax, and caspase-3 and decreases antiapoptotic protein Bcl-2. In addition, E-cadherin was increased, and 5-lipoxygenase (5-LOX), CCAAT/enhancer binding protein β (C/EBPβ), N-cadherin, vimentin, twist, and snail+slug were decreased. Cell cycle was arrested in G0/G1 phase, and S phase was reduced in a dose-dependent manner in both U251 and WJ1 cells. On human normal liver cells (LO2), KuA showed less cytotoxicity [62]. Nardostachys jatamansi Rhizome extract (NJRE) reduced caspase-3, caspase-9, and PARP. NJRE at lower dose (20~40 µg/mL) caused excessive nucleation, mitotic catastrophe, DNA fragmentation, and early apoptosis, while higher dose (60~80 µg/mL) induced late apoptosis and G0/G1 arrest [63]. Myricetin (MYR) is one of the natural herbal flavonoids, which has noticeable anticancer properties with nearly zero side effects. MYR-induced cytotoxicity caused glioblastoma cell death by mitochondrial apoptotic pathway. Treated with MYR, cytochrome c, Bcl-2, MDM2, K-Ras, Raf-1, and ERKs (ERK and pERK) are decreased, and Bax, cleaved caspase-3, caspase-9, and Bad are increased. Pluronic-based micelle encapsulation on MYR (MYR micelles (MYR-MCs)) strengthens the effect of MYR itself [64]. Lemon balm (Melissa officinalis) aqueous extract has a number of phenolic compounds, protocatechuic, caftaric, caffeic, ferulic, and cichoric acids and flavonoid luteolin-7-glucoside. At 50 µM–200 µM, it showed cytotoxic effect and initiated apoptotic cell death. The biggest amount of active compounds was extracted when using 70% ethanol and has the highest cytotoxic activity on glioblastoma cells. At lower concentrations, intracellular reactive species was decreased. By contrast, at higher concentration, intracellular reactive species was increased. Rosmarinic acid (RA) can be also be found in the dominant and predominant compound. RA showed cytotoxicity on glioblastoma cells. Its LC50 is 290.5 µM for 24 h and 171.3 µM for 48 h. 80–130 µM of RA caused an antioxidant effect and suppression of the cell proliferation. At higher than 200 µM, RA have a prooxidant effect and initiate necrotic cell death [65]. β-Escin is natural compound that is a selective inhibitor of glioblastoma-initiating cells (GIC) viability. β-Escin exhibited significant cytotoxicity in nine patient-derived GIC, while no substantial effect on the other human cancer or control cell lines is tested. Furthermore β-escin had stronger effect than current clinically used cytotoxic agents at reducing GIC growth. It triggers caspase-dependent cell death and causes a loss of stemness properties. But blocking apoptosis could not reduce the β-escin-induced effect in sphere formation or stemness marker activity. This result suggests that β-escin directly changes the stem identity of GIC, independent of inducing the cell death [66]. Acori Graminei Rhizoma is used for traditional medicine, which has beneficial effects on CNS disorders. Volatile oil of Acori Graminei Rhizoma (VOA) was tried on human glioblastoma multiforme (GBM) cells. VOA suppressed tumor cell growth greatly and showed very low effect on fibroblasts and human glial HEB cells. By VOA, caspase-dependent apoptosis, and p53/AMPK/mTOR signaling pathway autophagy was observed in p53 wild-type A172 cells, and also caspase-independent apoptosis and mTOR-independent pathway autophagy in p53 mutant U251 cells were examined [67]. Ginsenoside Rg3 significantly inhibits proliferation, arrests the cell cycle, and induces apoptosis in HUVEC through reducing VEGF and Bcl-2 expression by combining temozolomide (TMZ) [68]. Zataria multiflora Boiss (Lamiaceae) (ZM) has antioxidant and anti-inflammation activities. Several compounds like thymol, carvacrol, zatrinal, oleanolic acid, betulic acid, rosmarinic acid, monoterpenoids, sesquiterpenoids, p-cymene, and y-terpinen are found in it; above all, thymol and carvacrol are main compounds. After ZM extract treatment, antiproliferation effect of Ionizing radiation (IR) was strengthened only on human glioblastoma (A172) and it showed insignificant change on human nonmalignant fibroblast cell (HFFF2) [69]. Shikonin is an anthraquinone found from the root of lithospermum. After shikonin treatment on human glioblastoma cells, MMP-2, MMP-9, p-AKT, and p-PI3K decreased. However p-β-catenin Y333 against β-catenin was reduced significantly in the U87 cells, while it was increased in the U251 cells [70]. Propolis is a natural resinous product collected from various plant sources by honeybees. Prenylflavanone (propolin G) is isolated from Taiwanese propolis (TP). This compound induces apoptosis in brain cancer. Propolin G and TP extract protect cortical neurons against oxidative stress in rat [71]. Curcumin (diferuloylmethane) is a natural compound that can be found in turmeric (Curcuma longa). It is a well-known agent that has anticarcinogenic activity in tumor cells. Curcumin induces cell cycle arrest (G1 phase) and it has ERK and JNK MAPK/Elk-1/Egr-1 signal that is required for p53-independent transcriptional activation of p21Waf1/Cip1 in U-87MG glioblastoma cells [47]. Berberine, an isoquinoline plant alkaloid, has been used for the treatment of many diseases. It is isolated from traditional Chinese herbal medicine, Coptis chinensis, and Hydrastis canadensis [72]. Berberine induces G1 arrest and apoptosis in T98G cells. It is mediated through the disruption of the mitochondrial membrane potential and activation of caspase pathways [73]. Three benzopyrans, 6-isobutyryl-5,7-dimethoxy-2,2-dimethyl-benzopyran, 7-hydroxy-6-isobutyryl-5-methoxy-2,2-dimethyl benzopyran, and 5-hydroxy-6-isobutyryl-7-methoxy-2,2-dimethyl-benzopyran, are isolated from the chloroform extract of Hypericum polyanthemum. They induce cell cycle arrest G2/M phase by increasing sub-G1% in U-373MG [74].

3. ROS Generation of Natural Products

ROS generation is closely related to apoptosis [75]. Some natural products activated ROS generation in GBM (Table 2). Balanitin-6 (28%) and balanitin-7 (72%) are isolated Balanites aegyptiaca which is an African plant of medicinal interest. This compound has anticancer activities via depletion of [ATP]i. It leads to disorganization of actin cytoskeleton [76]. Obtusaquinone (OBT) activate cellular stress pathways and DNA damage via rapid increase in intracellular ROS levels [77]. γ-Mangostin in Garcinia mangostana induces ROS and activates NK cells [39]. Propolis significantly suppressed cell death and reactive oxygen species production from homocysteine (Hcy), in dose-dependent manner. In an in vivo study, propolis ingestion improved cognitive function from cognitive dysfunction of Hcy which caused hyperhomocysteinemia [78].

Family namesMedical plantsCompounds/extractsDose/durationTarget molecules and additional efficacyCell linesReferences

ZygophyllaceaeBalanites aegyptiacaBalanitin-6 (28%), balanitin-7 (72%)830 nM for 24, 48, 72 h↓ATP (disorganization of actin cytoskeleton)U373 [76]

Obtusaquinone(In vitro)
5 µM for 24 h (in vivo)
7.5 mg/kg for 21 days
↑ROS, p53, caspase 3/7
ERK pathway
Gli36, U87 MG, U251, GBM8, GBM11/5, VU147 [77]

ClusiaceaeGarcinia mangostanaγ-Mangostin80 μM for 8 h↑NK cell, ROS
↓PGE2, COX-2, NO,
U87 MG, GBM 8401 [39]

N/ABrazilian propolis (Pro) (not specific plant)[Homocysteine (Hcy)] to provoke cognitive dysfunction100 μM DL-Hcy + 0, 0.2, 0.4, 0.8, 1.6, 3.2 μg/mL for 72 h (intracellular ROS detection)
(after age 12 weeks mice + 1 week adaption) 0% Pro + Hcy(x), 0% Pro + Hcy(o), 0.25% Pro + Hcy(o), 0.05% Pro + Hcy(o) for 5, 14, 27 week (animal experiment)
0, 100 μM Hcy + 0, 0.27, 1.38 μg/mL Pro (final concentration each) for 0, 7, 11, 14, 17, 21, 24 days
↑relative fluorescence intensity
↓relative ROS intensity, in vivo Plasma Hcy concentrations, in vitro amyloids formation
Propolis intake made rats recovered from Hcy induced cognitive dysfunction
Neuroblastoma SH-SY5Y, glioblastoma U-251MG [78]

4. Antiangiogenesis Effect of Natural Products

A range of natural products exerted antiangiogenesis effect (Table 3 and Figure 1). The antiangiogenesis drug ginsenoside Rg3 (RG3) shows additive effects by combining with low-dose metronomic (LDM) temozolomide (TMZ). Combined use of TMZ with RG3 inhibited proliferation of HUVEC and decreased VEGFA and BCL-2 expression in HUVEC. Also the antiangiogenesis effect was also evaluated in the rat model of orthotopic glioma allograft, based upon markers including relative cerebral blood volume (rCBV) by magnetic resonance imaging (MRI) and microvessel density (MVD)/CD34 staining [68]. Mango ginger (Curcuma amada Roxb.) is one of the Curcuma species, the popular herbal medicine for anticancer. But it is a less-investigated herb for anticancer properties than other related Curcuma species. Supercritical CO2 extract of mango ginger treatment showed antiangiogenesis effect by downregulating VEGF [79]. Red grape skin polyphenolic extract has been issued from its antiangiogenic, anti-inflammatory, and anticancer activity. The extract showed decrease of the tube network formation in HUVEC by Matrigel model. It inhibited S1P- and the VEGF-induced endothelial cell migration [80]. Cannabinoids, the active components of marijuana and their derivatives, are currently investigated due to their potential therapeutic application for the management of many different diseases, including cancer. Specifically, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)—the two major ingredients of marijuana—have been shown to inhibit tumor growth in a number of animal models of cancer, including glioma. Treatment of U87-derived xenografts with THC- or CBD-loaded microparticles or with a mixture of THC and CBD microparticles decreased tumor vascularization as determined by immunostaining with the endothelial cell marker CD31 [28].

Family namesMedical plantsCompounds/extractsDose/durationTarget molecules and additional efficacyCell linesReferences

AraliaceaePanax ginsengGinsenoside Rg30–180 μg/ml
for 72 h (in vitro)
10 mg/kg/day
for 8 days (in vivo)
Inhibit HUVEC proliferation, less increase rCBV
Rat C6 glioma cells [68]

ZingiberaceaeCurcuma amada Supercritical CO2 extract0–100 μg/ml
for 72 h
0–20 μg/ml
for 24 h

VitaceaeVitis viniferaRed grape skin polyphenolic extract0–25 μg/ml
for 24 h
↓tube network formation, VEGF, S1P, ERK, p38/MAPK phosphorylation, S1P-induced PAF synthesisU87MG [80]

CannabaceaeCannabis sativaΔ9-Tetrahydrocannabinol, cannabidiol7.5 mg/kg/day
for 22 days
↓tumor vascularization (CD31 immunostaining)U87MG [28]

5. Antimetastasis Effect of Natural Products

Metastasis is responsible for a majority of cancer-related deaths. Tumor invasion of the surrounding tissue and subsequent metastasis results from a multistep process that includes proteolytic degradation of the surrounding extracellular matrix (ECM), allowing malignant cells to move into and through the ECM and basement membrane. The epithelial-to-mesenchymal transition (EMT) is the crucial step for cancer cells to initiate the metastasis and could be induced by many growth factors. Glioblastoma multiforme (GBM) is one of the most lethal types of tumors and is highly metastatic and invasive. Type IV collagenase matrix metalloproteinases (MMPs), in particular, MMP-2 and MMP-9 and gelatinase A and gelatinase B, respectively, have been found to promote invasion and metastasis of malignant tumors. Various natural products showed antimetastatic effects (Table 4 and Figure 2). Epigallocatechin gallate (EGCG) is the main polyphenol in green tea extract (GTE) [81]. At human glioblastoma (T-98G) cells, MMP-2 and MMP-9 expression decreased with increased concentration of treatment, with the nutrient mixture being most effective, followed by green tea extract and then EGCG [82]. Quercetin (QE), baicalein (BE), and myricetin (ME) are widely used from flavonoids extracted from plants, herbs, and fruits. They induce inhibition of DPPH radical production, PGE2, TPA-induced COX-2 protein, MMP-9 enzyme activity, and peroxide production. QE, BE, and ME can block migration/invasion by GBM cells [83]. Sargassum (Sargassaceae, Fucales) is a genus of brown seaweed that is found in the ocean. Previous research on Sargassum spp. extracts has been reported to exhibit anticancer, antibacterial, antifungal, antiviral, anti-inflammatory, anticoagulant, antioxidant, hepatoprotective, and neuroprotective activities. However, the pharmacological effect of extracts from Sargassum serratifolium (S. serratifolium) has not been thoroughly studied in glioblastoma. Western blot analysis, Τranswell invasion, and wound-healing assays were performed to demonstrate the effects of HES on cell migration and invasion of the U87MG cells. In Western blot analysis, the expression levels of MMP-2 and MMP-9 were decreased in the glioblastoma cells following treatment with HES in a dose-dependent manner [84]. Osthole, a coumarin derivative isolated from the fruit of Cnidium monnieri (L.) Cusson, has been widely used for the treatment of skin diseases and gynecopathy. Osthole suggested an anticaner strategy that targets IGF-1 induced EMT. Osthole reversed IGF-1-induced morphological changes, upregulated the expression of epithelial markers, and downregulated the expression of mesenchymal markers. Osthole significantly suppressed the IGF-1-induced upregulation of MMP-2 and MMP-9 in a dose- and time-dependent manner. Moreover, wound-healing assay also showed that osthole could inhibit IGF-1-induced migration of GBM8401 cells [85]. Resveratrol (RES) is a polyphenolic antioxidant found in peanuts, grapes, and red wine, and although parent RES bioavailability might be insufficient to elicit systemic levels commensurate with cancer chemopreventive efficacy, the antioncogenic properties of RES in cells in vitro and in rodent models have been amply documented [86]. RES suppressed the adhesion, invasion, and migration of glioblastoma-initiating cells (GICs) in vitro and in vivo. It inhibited the invasion of GICs via the inhibition of PI3K/Akt/NF-κB signal transduction and the subsequent suppression of MMP-2 expression [86].

Family namesMedical plantsCompounds/extractsDose/durationTarget molecules and additional efficacyCell linesReferences

TheaceaeCamelliasinensis (green tea)Vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract (80% polyphenol) 1000 mg; selenium 30 μg; copper 2 mg; manganese 1 mg0–1000 μg/ml↑TIMP-2
↓MMP-2, MMP-9, uPA
LN-18, T-98G, A-172[81]

TheaceaeCamellia sinensisEpigallocatechin gallate (EGCG)50–500 μg/ml↓-2, MMP-9T-98G[82]

SargassaceaeSargassum serratifoliumHexane, ethanol, ethyl extract5–15 μg/ml
for 12–24 h
↓ MMP-2, MMP-9, C-Raf, MEK, ERK, phospho-ERK, wound area, invasive cellsU87MG[84]

ApiaceaeCnidium monnieriOsthole20–80 μM
for 24 h
↓MMP-2, MMP–9
Inhibit IGF-1-induced EMT

Peanuts, grapes, red wineResveratrol5–20 μM
for 48 h
↓MMP-2, NF-κB pathway, PI3K/AKT signaling pathwayGlioblastoma-initiating cells (GICs)[86]

Flavonoids (plants, herbs, fruits)Quercetin (QE), baicalein (BE), myricetin (ME)0–50 μM
for 30 min
↓ ERK-activated COX-2/PGE2, MMP-9U87MG[83]

6. MiRNA Regulation of Natural Products

MiRNA expression is one of important mechanisms in development of cancer. Recently studies on natural compounds reported cancer suppressive effect of altering miRNA expression, which is a new strategy for cancer treatment (Table 5) [51].

Family namesMedical plantsCompounds/extractsDose/durationTarget molecules and additional efficacyCell linesReferences

OleaceaeOlea europaeaOleuropein1 mg/ml, 2 mg/ml for 24 h↑miR-153, miR-145, miR-137T98G,

MoraceaeFicus caricaProtocatechuic acid0.25 mg/ml for 24 h↑let-7d, VEGF
U-138 MG,
U-87 MG

BoraginaceaeLithospermum erythrorhizonShikonin2 mg/kg for 24 h↑miR-143, BAG3GSC[87]

BerberidaceaeBerberis amurensisBerbamine5 mM for 24 h↑caspase-3, PARP, miR-4284, JNK1, JNK 2, SAPK, phosphorylated c- Jun, total c-Fos
apoptosis, JNK-c-Jun/AP-1 signaling pathway
PBT003, PBT008, PBT022,

OleaceaeOlea europaeaOleuropein1 mg/ml for 24 h, 48 hmiR-181b, miR-153, miR-145, miR-137, ↑let-7dT98G[88]

ZingiberaceaeCurcuma longaCurcumin (diferuloylmethane)20 μM for 72 h↑miR-146a
U-87 MG[89]

Ficus carica Latex (FCL) induced the expression of let-7d, targeting epithelial mesenchymal transition of HMGA2 gene, in GBM cells [52].

Shikonin, a natural compound from Chinese medical herb, showed enhanced apoptotic efficacy by overexpressing miR-143 in GSC cells. The antitumor effects of miR-143 were related to BAG3 expression in GSC cells [87]. Berbamine is a natural alkaloid derived from the traditional Chinese medicine, which showed inhibition of cell viability and apoptotic efficacy in GBM stem-like cells by increasing miR-4284 expression [56]. MiRNA modulating effect of Olea europaea (OLE) regulates the expression of miRNA including miR-181b, miR-153, miR-145, miR137, and let-7d. By upregulating these miRNAs, OLE induced antiproliferative effects on GBM cells. Furthermore, synergetic effect was shown in combination treatment of OLE and TMZ [88]. Curcumin enhanced cytotoxicity in GBM cells by upregulating miR-146. The regulation of miR-146/NFκB axis sensitized the TMZ-induced cell death in GBM cells [89].

7. Multidrug Resistance and Natural Products

Multidrug resistance (MDR) is a major cause of failure in cancer chemotherapies which is presented by numerous cancer cells by withstanding increasing dose of drugs. Consequently, novel compounds derived from natural products are suggested as potential solutions of MDR (Table 6). Withaferin A is a steroidal lactone derived from natural products, demonstrating oxidative mechanism related to AKT/mTOR pathway modulation, MAPK survival, and proliferation pathway in TMZ-resistant GBM cells [57]. Aframomum arundinaceum extract [90], 8-hydroxycudraxanthone G, cudraxanthone I [91], and sobavachalcone [90] were observed to have hypersensitivity, which means lower drug resistance, to GBM cells.

Family namesMedical plantsCompounds/extractsDose/durationTarget molecules and additional efficacyCell linesReferences

SolanaceaeWithania somniferaWithaferin A2.5 μM, 1 μM for 24 h↑ERK1/2, HSP32, HSP70
AKT, mTOR, p70 S6K, c-Met, EGFR, ↓Her2, HSF1
Oxidative stress, heat shock response, AKT/mTOR pathway, MGMT
U87, U251, T98G[57]

ZingiberaceaeAframomum arundinaceumMethanol extract40 μg/mL for 72 hCollateral sensitivity (hypersensitivity)U87MG.ΔEGFR[90]

ClusiaceaeGarcinia nobilis8-Hydroxycudra-xanthone G, cudraxanthone I22.49 μM for 24 hCollateral sensitivity (hypersensitivity)U87MG[91]

MoraceaeDorstenia barteriIsobavachalcone23.78 μM for 24 hCollateral sensitivity (hypersensitivity)U87MG [90]

8. Clinical Trials of Natural Production against GBM

Patients with GBM have short survival and most of them develop recurrent or progressive disease after their initial treatments [92]. Two clinical trials on glioblastoma patients were examined (Table 7), but since the clinical trials were progressed no more than phase II, further evaluation of the clinical aspects of these drugs should be reconsidered.

PhaseTitleCurrent stateFamily namesMedical plantsCompounds/extractsAdditional therapyEvaluationSurvivalPatientsReferences

Phase 1,
Phase 2
Patupilone (EPO 906) in patients with recurrent or progressive glioblastoma multiforme prior to and after secondary resection: an open-label phase I/II trialCompletedMyxobacteriumSorangium cellulosumPatupiloneSalvage treatment after patupilone consisted of bevacizumab, CCNU, a second RT round or surgeryProgression-free survival (PFS), overall survival (OS) at 6 months, patupilone concentration in tumor tissue/toxicity, patupilone concentration in plasma and translational analyses for predictive biomarkers, Aschen Aphasia Test, Rey Auditory-Verbal Learning Test, Rey Visual Design Learning Test, Rey-Osterrieth Complex analyses for predictive biomarkersMedian 85 weeks/median PFS 6 weeks9 patients/age 42–68 yrs[92]

Phase 2Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytomaCompletedEnterobacteriaceaeSerratia marcescensImuVertRadiation therapyPhysical examination, KPS, assessment of weight, CBC count with differential, coagulation profile, serum chemistries, CT, MRI, thallium SPECT, time to progression of tumorMedian survival 69 weeks/median time to progression 11 weeks11 patients/newly diagnosed glioblastoma multiforme (GBM)/age 42–69 yrs[93]

ImuVert is a biologic response modifier derived from S. marcescens bacteria. A study suggested that ImuVert treatment has minimal toxicity and is well tolerated and contributing to prolonged survival properties in patients newly diagnosed as GBM. The patient survival was slightly prolonged after the treatment with median survival 69 weeks and median time to progression 11 weeks [93]. Another clinical trial with patupilone, which is a natural microtubule-stabilizing cytotoxic agent, showed prolonged survival in GBM patients after their second surgeries. 2 out of 9 patients were recurrence-free after the treatment for 9.75 and 22 months each. Moreover, median survival of all patients was 85 months after their first surgeries. The result suggests that patupilone treatment can be given to recurrent GBM patients before and after surgery safely [92].

9. Conclusion

In this review, we categorized precedent studies that encompass various mechanisms of natural products, such as suppression toward apoptosis, angiogenesis, metastasis, ER stress, and MDR, taking into view the standardization of natural product-derived drugs and evaluation of drug doses that display maximum effectiveness [94].

It is well known that GBM is far more difficult to treat than other malignant cancers, mainly due to its pathological properties [95]. Consequently our review puts emphasis on shedding light on the potential of natural products for GBM treatment by solving the impending problem regarding the limitations of current glioblastoma therapy. Certain natural products shown in our review have potent antiglioblastoma properties that have been tested in in vitro and in vivo laboratory situations. Clinical trials also exhibit compelling effects, although they are still undergoing further evaluation, and their cases are minor in number. More preclinical and clinical studies should be conducted to elucidate the effects and mechanisms of natural products.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

M. N. Park, H. S. Song, and Y. Hwang wrote the introduction and discussion section. M. Kim, M. J. Lee, W. Cho., H. J. Lee, C. H. Hwang, and S. Kim collected the data and wrote result. H. S. Song, B. Kang, and B. Kim revised the manuscript. B. Kim designed and supervised the manuscript. Moon Nyeo Park and Hyo Sook Song contributed equally to this work.


This work was supported by a grant from Kyung Hee University in 2015 (KHU-20151825) and Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education (2016R1D1A1B03933656) and Ministry of Science, ICT & Future Planning (2016R1D1A1B03933656).


  1. F. Shi, H. Guo, R. Zhang et al., “The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines,” Neuroscience, vol. 346, pp. 298–308, 2017. View at: Publisher Site | Google Scholar
  2. Cancer Genome Atlas Research Network, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways,” Nature, vol. 455, no. 7216, pp. 1061–1068, 2008. View at: Publisher Site | Google Scholar
  3. P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” The New England Journal of Medicine, vol. 359, no. 5, pp. 492–507, 2008. View at: Publisher Site | Google Scholar
  4. R. J. Klement and C. E. Champ, “Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels,” Brain, vol. 140, no. 3, p. e16, 2017. View at: Publisher Site | Google Scholar
  5. R. E. McLendon and E. C. Halperin, “Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?” Cancer, vol. 98, no. 8, pp. 1745–1748, 2003. View at: Publisher Site | Google Scholar
  6. T. T. Batchelor, D. A. Reardon, J. F. De Groot, W. Wick, and M. Weller, “Antiangiogenic therapy for glioblastoma: current status and future prospects,” Clinical Cancer Research, vol. 20, no. 22, pp. 5612–5619, 2014. View at: Publisher Site | Google Scholar
  7. E. J. Vaios, B. V. Nahed, A. Muzikansky, A. Fathi, and J. Dietrich, “Bone marrow response as a potential biomarker of outcomes in glioblastoma patients,” Journal of Neurosurgery, vol. 18, supplement 6, pp. 1–7, 2016. View at: Publisher Site | Google Scholar
  8. F. Atif, N. R. Patel, S. Yousuf, and D. G. Stein, “The synergistic effect of combination progesterone and temozolomide on human glioblastoma cells,” PLoS ONE, vol. 10, no. 6, Article ID e0131441, 2015. View at: Publisher Site | Google Scholar
  9. S. Osuka and E. G. Van Meir, “Overcoming therapeutic resistance in glioblastoma: The way forward,” The Journal of Clinical Investigation, vol. 127, no. 2, pp. 415–426, 2017. View at: Publisher Site | Google Scholar
  10. G. L. Semenza, “A new weapon for attacking tumor blood vessels,” The New England Journal of Medicine, vol. 358, no. 19, pp. 1990–2067, 2008. View at: Publisher Site | Google Scholar
  11. D. E. Cohn, K. H. Kim, K. E. Resnick, D. M. O'Malley, and J. M. Straughn Jr., “At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis,” Journal of Clinical Oncology, vol. 29, no. 10, pp. 1247–1251, 2011. View at: Publisher Site | Google Scholar
  12. S. Hemalswarya and M. Doble, “Potential synergism of natural products in the treatment of cancer,” Phytotherapy Research, vol. 20, no. 4, pp. 239–249, 2006. View at: Publisher Site | Google Scholar
  13. K. Bae, J.-H. Park, J. Kim et al., “Traditional oriental herbal medicine and natural killer cells for cancer patients: a systematic review and meta-analysis,” Phytotherapy Research, vol. 31, no. 4, pp. 519–532, 2017. View at: Publisher Site | Google Scholar
  14. S. S. Ajazuddin, “Applications of novel drug delivery system for herbal formulations,” Fitoterapia, vol. 81, no. 7, pp. 680–689, 2010. View at: Publisher Site | Google Scholar
  15. L. C. Hou, A. Veeravagu, A. R. Hsu, and V. C. K. Tse, “Recurrent glioblastoma multiforme: a review of natural history and management options,” Neurosurgical Focus, vol. 20, no. 4, p. E5, 2006. View at: Google Scholar
  16. J. D. Phillipson, “Phytochemistry and pharmacognosy,” Phytochemistry, vol. 68, no. 22–24, pp. 2960–2972, 2007. View at: Publisher Site | Google Scholar
  17. M. Zhang, G. Ye, J. Li, and Y. Wang, “Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy,” Brain Tumor Pathology, vol. 32, no. 4, pp. 229–236, 2015. View at: Publisher Site | Google Scholar
  18. W.-H. Lee, J.-S. Jin, W.-C. Tsai et al., “Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma,” Pathobiology, vol. 73, no. 3, pp. 141–148, 2006. View at: Publisher Site | Google Scholar
  19. B. Kim, S. K. Srivastava, and S.-H. Kim, “Caspase-9 as a therapeutic target for treating cancer,” Expert Opinion on Therapeutic Targets, vol. 19, no. 1, pp. 113–127, 2015. View at: Publisher Site | Google Scholar
  20. Y.-L. Lin, W.-L. Lai, H.-J. Harn et al., “The methanol extract of angelica sinensis induces cell apoptosis and suppresses tumor growth in human malignant brain tumors,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 394636, 9 pages, 2013. View at: Publisher Site | Google Scholar
  21. K. Hostanska, J. Reichling, S. Bommer, M. Weber, and R. Saller, “Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 56, no. 1, pp. 121–132, 2003. View at: Publisher Site | Google Scholar
  22. N. M. Tsai, Y. L. Chen, C. C. Lee et al., “The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo,” Journal of Neurochemistry, vol. 99, no. 4, pp. 1251–1262, 2006. View at: Publisher Site | Google Scholar
  23. P. J. Ferguson, E. M. Kurowska, D. J. Freeman, A. F. Chambers, and J. Koropatnick, “In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract,” Nutrition and Cancer, vol. 56, no. 1, pp. 86–94, 2006. View at: Publisher Site | Google Scholar
  24. R. Mishra and G. Kaur, “Aqueous ethanolic extract of Tinospora cordifolia as a potential candidate for differentiation based therapy of glioblastomas,” PLoS ONE, vol. 8, no. 10, Article ID e78764, pp. 1–13, 2013. View at: Publisher Site | Google Scholar
  25. I. O. Racoma, W. H. Meisen, Q.-E. Wang, B. Kaur, and A. A. Wani, “Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells,” PLoS ONE, vol. 8, no. 9, Article ID e72882, 2013. View at: Publisher Site | Google Scholar
  26. A. Wieland, D. Trageser, S. Gogolok et al., “Anticancer effects of niclosamide in human glioblastoma,” Clinical Cancer Research, vol. 19, no. 15, pp. 4124–4136, 2013. View at: Publisher Site | Google Scholar
  27. D.-Y. Lee, M.-K. Lee, G.-S. Kim, H.-J. Noh, and M.-H. Lee, “Brazilin inhibits growth and induces apoptosis in human glioblastoma cells,” Molecules, vol. 18, no. 2, pp. 2449–2457, 2013. View at: Publisher Site | Google Scholar
  28. D. Hernán Pérez de la Ossa, M. Lorente, M. E. Gil-Alegre et al., “Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme,” PLoS ONE, vol. 8, no. 1, Article ID e54795, 2013. View at: Publisher Site | Google Scholar
  29. M. T. Empl, S. Macke, P. Winterhalter et al., “The growth of the canine glioblastoma cell line D-GBM and the canine histiocytic sarcoma cell line DH82 is inhibited by the resveratrol oligomers hopeaphenol and r2-viniferin,” Veterinary and Comparative Oncology, vol. 12, no. 2, pp. 149–159, 2014. View at: Publisher Site | Google Scholar
  30. D.-H. Lee, T. H. Lee, C. H. Jung, and Y.-H. Kim, “Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells,” Cellular Signalling, vol. 24, no. 11, pp. 2216–2225, 2012. View at: Publisher Site | Google Scholar
  31. N. A. A. Thani, B. Sallis, R. Nuttall et al., “Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin,” Oncology Reports, vol. 28, no. 4, pp. 1435–1442, 2012. View at: Publisher Site | Google Scholar
  32. K. J. Lim, K. Rajan, and C. G. Eberhart, “Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and notch signaling,” Anticancer Reseach, vol. 32, no. 7, pp. 2689–2696, 2012. View at: Google Scholar
  33. Y. Li, P. Zhang, F. Qiu et al., “Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells,” Life Sciences, vol. 90, no. 25-26, pp. 962–967, 2012. View at: Publisher Site | Google Scholar
  34. C. H. Kuder, R. M. Sheehy, J. D. Neighbors, D. F. Wiemer, and R. J. Hohl, “Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification,” Molecular Pharmacology, vol. 82, no. 1, pp. 9–16, 2012. View at: Publisher Site | Google Scholar
  35. M. Khan, B. Yu, A. Rasul et al., “Jaceosidin induces apoptosis in U87 glioblastoma cells through G2/M phase arrest,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 703034, 12 pages, 2012. View at: Publisher Site | Google Scholar
  36. E. C. Filippi-Chiela, E. S. Villodre, L. L. Zamin, and G. Lenz, “Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells,” PLoS ONE, vol. 6, no. 6, Article ID e20849, 2011. View at: Publisher Site | Google Scholar
  37. M.-Y. Lee, M.-H. Liao, Y.-N. Tsai, K.-H. Chiu, and H.-C. Wen, “Identification and anti-human glioblastoma activity of tagitinin C from tithonia diversifolia methanolic extract,” Journal of Agricultural and Food Chemistry, vol. 59, no. 6, pp. 2347–2355, 2011. View at: Publisher Site | Google Scholar
  38. L.-F. Chang, P.-C. Lin, L.-I. Ho et al., “Overexpression of the orphan receptor Nur77 and its translocation induced by PCH4 may inhibit malignant glioma cell growth and induce cell apoptosis,” Journal of Surgical Oncology, vol. 103, no. 5, pp. 442–450, 2011. View at: Publisher Site | Google Scholar
  39. H.-F. Chang, W.-T. Huang, H.-J. Chen, and L.-L. Yang, “Apoptotic effects of γ-mangostin from the fruit hull of Garcinia mangostana on human malignant glioma cells,” Molecules, vol. 15, no. 12, pp. 8953–8966, 2010. View at: Publisher Site | Google Scholar
  40. S. Karmakar, N. L. Banik, and S. K. Ray, “Molecular mechanism of inositol hexaphosphate-mediated apoptosis in human malignant glioblastoma T98G cells,” Neurochemical Research, vol. 32, no. 12, pp. 2094–2102, 2007. View at: Publisher Site | Google Scholar
  41. D. Chaudhuri, N. B. Ghate, S. S. Singh, and N. Mandal, “Methyl gallate isolated from Spondias pinnata exhibits anticancer activity against human glioblastoma by induction of apoptosis and sustained extracellular signal-regulated kinase 1/2 activation,” Pharmacognosy Magazine, vol. 11, no. 42, pp. 269–276, 2015. View at: Publisher Site | Google Scholar
  42. M. T. Gentile, C. Ciniglia, M. G. Reccia et al., “Ruta graveolens L. induces death of glioblastoma cells and neural progenitors, but not of neurons, via ERK 1/2 and AKT activation,” PLoS ONE, vol. 10, no. 3, Article ID e0118864, 2015. View at: Publisher Site | Google Scholar
  43. T.-Y. Lin, C.-C. Lee, K.-C. Chen, C.-J. Lin, and C.-M. Shih, “Inhibition of RNA transportation induces glioma cell apoptosis via downregulation of RanGAP1 expression,” Chemico-Biological Interactions, vol. 232, pp. 49–57, 2017. View at: Publisher Site | Google Scholar
  44. M. Guerram, Z.-Z. Jiang, L. Sun, X. Zhu, and L.-Y. Zhang, “Antineoplastic effects of deoxypodophyllotoxin, a potent cytotoxic agent of plant origin, on glioblastoma U-87 MG and SF126 cells,” Pharmacological Reports, vol. 67, no. 2, pp. 245–252, 2015. View at: Publisher Site | Google Scholar
  45. H. Dang, J. Wang, J. X. Cheng et al., “Efficacy of local delivery of ardipusilloside I using biodegradable implants against cerebral tumor growth,” American Journal of Cancer Research, vol. 5, no. 1, pp. 243–254, 2015. View at: Google Scholar
  46. C. Ramachandran, I. V. Lollett, E. Escalon, K.-W. Quirin, and S. J. Melnick, “Anticancer potential and mechanism of action of mango ginger (Curcuma amada Roxb.) supercritical CO2 extract in human glioblastoma cells,” Evidence-Based Complementary and Alternative Medicine, vol. 20, no. 2, pp. 109–119, 2015. View at: Publisher Site | Google Scholar
  47. A. Zanotto-Filho, E. Braganhol, K. Klafke et al., “Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas,” Cancer Letters, vol. 358, no. 2, pp. 220–231, 2015. View at: Publisher Site | Google Scholar
  48. Y. Zhang, R.-F. Xie, Q.-G. Xiao, R. Li, X.-L. Shen, and X.-G. Zhu, “Hedyotis diffusa Willd extract inhibits the growth of human glioblastoma cells by inducing mitochondrial apoptosis via AKT/ERK pathways,” Journal of Ethnopharmacology, pp. 404–411, 2014. View at: Publisher Site | Google Scholar
  49. L. Yang, Y. Wang, H. Guo, and M. Guo, “Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma,” Cell Biochemistry and Biophysics, vol. 71, no. 3, pp. 1379–1385, 2015. View at: Publisher Site | Google Scholar
  50. Y. Wang, W. Liu, X. He, and Z. Fei, “Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK,” Cell Biochemistry and Biophysics, vol. 71, no. 2, pp. 701–706, 2014. View at: Publisher Site | Google Scholar
  51. G. Tezcan, B. Tunca, A. Bekar et al., “Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression,” American Journal of Cancer Research, vol. 4, no. 5, pp. 572–590. View at: Google Scholar
  52. G. Tezcan, B. Tunca, A. Bekar et al., “Ficus carica latex prevents invasion through induction of let-7d expression in gbm cell lines,” Cellular and Molecular Neurobiology, vol. 35, no. 2, pp. 175–187, 2015. View at: Publisher Site | Google Scholar
  53. Y. Zhang, X. Ren, M. Shi et al., “Downregulation of STAT3 and activation of MAPK are involved in the induction of apoptosis by HNK in glioblastoma cell line U87,” Oncology Reports, vol. 32, no. 5, pp. 2038–2046, 2014. View at: Publisher Site | Google Scholar
  54. A. I. Elkady, R. A. E. H. Hussein, and O. A. Abu-Zinadah, “Effects of crude extracts from medicinal herbs Rhazya stricta and Zingiber officinale on growth and proliferation of human brain cancer cell line in vitro,” BioMed Research International, vol. 2014, Article ID 260210, 16 pages, 2014. View at: Publisher Site | Google Scholar
  55. R. Wang, X. Xiao, P.-Y. Wang et al., “Stimulation of autophagic activity in human glioma cells by anti-proliferative ardipusilloside i isolated from Ardisia pusilla,” Life Sciences, vol. 110, no. 1, pp. 15–22, 2014. View at: Publisher Site | Google Scholar
  56. F. Yang, S. Nam, C. E. Brown, R. Zhao, and R. Starr, “A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling,” PLoS ONE, vol. 9, no. 4, Article ID e94443, 2014. View at: Publisher Site | Google Scholar
  57. P. T. Grogan, J. N. Sarkaria, B. N. Timmermann, and M. S. Cohen, “Oxidative cytotoxic agent withaferin a resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation,” Investigational New Drugs, vol. 32, no. 4, pp. 604–617, 2014. View at: Publisher Site | Google Scholar
  58. R. Dasari, L. M. Y. Banuls, M. Masi et al., “C1,C2-ether derivatives of the Amaryllidaceae alkaloid lycorine: Retention of activity of highly lipophilic analogues against cancer cells,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 3, pp. 923–927, 2014. View at: Publisher Site | Google Scholar
  59. S. Shojaei, A. Kiumarsi, A. R. Moghadam, J. Alizadeh, H. Marzban, and S. Ghavami, “Perillyl Alcohol (Monoterpene Alcohol), Limonene,” Enzymes, vol. 36, pp. 7–32, 2014. View at: Publisher Site | Google Scholar
  60. B. Singh, S. K. Guru, S. Kour et al., “Synthesis, antiproliferative and apoptosis-inducing activity of thiazolo[5,4-d]pyrimidines,” European Journal of Medicinal Chemistry, vol. 70, pp. 864–874, 2013. View at: Publisher Site | Google Scholar
  61. S.-F. Tsai, M. Tao, L.-I. Ho et al., “Isochaihulactone-induced DDIT3 causes ER stress-PERK independent apoptosis in glioblastoma multiforme cells,” Oncotarget , vol. 8, no. 3, pp. 4051–4061, 2017. View at: Publisher Site | Google Scholar
  62. Q. Wang, H. Li, Z. Sun et al., “Kukoamine A inhibits human glioblastoma cell growth and migration through apoptosis induction and epithelial-mesenchymal transition attenuation,” Scientific Reports, vol. 6, Article ID 36543, 2016. View at: Publisher Site | Google Scholar
  63. H. Kapoor, N. Yadav, M. Chopra, S. Mahapatra, and V. Agrawal, “Strong anti-tumorous potential of nardostachys jatamansi rhizome extract on glioblastoma and in silico analysis of its molecular drug targets,” Current Cancer Drug Targets, vol. 17, no. 1, pp. 74–88, 2016. View at: Publisher Site | Google Scholar
  64. X.-J. Tang, K.-M. Huang, H. Gui et al., “Pluronic-based micelle encapsulation potentiates myricetin-induced cytotoxicity in human glioblastoma cells,” International Journal of Nanomedicine, vol. 11, pp. 4991–5002, 2016. View at: Publisher Site | Google Scholar
  65. K. Ramanauskiene, R. Raudonis, and D. Majiene, “Rosmarinic acid and melissa officinalis extracts differently affect glioblastoma cells,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1564257, 9 pages, 2016. View at: Publisher Site | Google Scholar
  66. E. Harford-Wright, N. Bidère, and J. Gavard, “β-escin selectively targets the glioblastoma-initiating cell population and reduces cell viability,” Oncotarget , vol. 7, no. 41, pp. 66865–66879, 2016. View at: Publisher Site | Google Scholar
  67. L. Chen, Z. Jiang, H. Ma et al., “Volatile oil of Acori Graminei Rhizoma-induced apoptosis and autophagy are dependent on p53 status in human glioma cells,” Scientific Reports, vol. 6, Article ID 21148, 2016. View at: Publisher Site | Google Scholar
  68. C. Sun, Y. Yu, L. Wang et al., “Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro,” Journal of Experimental & Clinical Cancer Research, vol. 53, no. 32, p. 32, 2016. View at: Publisher Site | Google Scholar
  69. A. Aghamohammadi, S. J. Hosseinimehr, A. Ghasemi, M. Azadbakht, and T. A. Pourfallah, “Radiosensitization effects of a Zataria multiflora extract on human glioblastoma cells,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 16, pp. 7285–7290, 2015. View at: Publisher Site | Google Scholar
  70. F.-Y. Zhang, F.-Y. Zhang, Y. Hu et al., “Shikonin inhibits the migration and invasion of human glioblastoma cells by targeting phosphorylated β-catenin and phosphorylated PI3K/Akt: a potential mechanism for the anti-glioma efficacy of a traditional Chinese herbal medicine,” International Journal of Molecular Sciences, vol. 16, no. 10, pp. 23823–23848, 2015. View at: Publisher Site | Google Scholar
  71. W.-J. Huang, C.-H. Huang, C.-L. Wu et al., “Propolin G, a prenylflavanone, isolated from Taiwanese propolis, induces caspase-dependent apoptosis in brain cancer cells,” Journal of Agricultural and Food Chemistry, vol. 55, no. 18, pp. 7366–7376, 2007. View at: Publisher Site | Google Scholar
  72. S. Kamath, M. Skeels, and A. Pai, “Significant differences in alkaloid content of Coptis chinensis (Huanglian), from its related American species,” Chinese Medicine, vol. 4, article 1749, p. 17, 2009. View at: Publisher Site | Google Scholar
  73. K.-S. Eom, J.-M. Hong, M.-J. Youn et al., “Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway,” Biological & Pharmaceutical Bulletin, vol. 31, no. 4, pp. 558–562, 2008. View at: Publisher Site | Google Scholar
  74. A. B. F. Ferraz, S. A. L. Bordignon, C. Staats, J. Schripsema, and G. Lino von Poser, “Benzopyrans from Hypericum polyanthemum,” Phytochemistry, vol. 57, no. 8, pp. 1227–1230, 2001. View at: Publisher Site | Google Scholar
  75. J. Kim, M. Yun, E.-O. Kim et al., “Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers,” British Journal of Pharmacology, vol. 173, no. 6, pp. 1033–1044, 2016. View at: Publisher Site | Google Scholar
  76. C. Gnoula, V. Mégalizzi, N. De Nève et al., “Balanitin-6 and -7: Diosgenyl saponins isolated from Balanites aegyptiaca Del. display significant anti-tumor activity in vitro and in vivo,” International Journal of Oncology, vol. 32, no. 1, pp. 5–15, 2008. View at: Publisher Site | Google Scholar
  77. C. E. Badr, S. Van Hoppe, H. Dumbuya, L.-A. Tjon-Kon-Fat, and B. A. Tannous, “Targeting cancer cells with the natural compound obtusaquinone,” Journal of the National Cancer Institute, vol. 105, no. 9, pp. 643–653, 2013. View at: Publisher Site | Google Scholar
  78. Y. Miyazaki, Y. Sugimoto, A. Fujita, and H. Kanouchi, “Ethanol extract of Brazilian propolis ameliorates cognitive dysfunction and suppressed protein aggregations caused by hyperhomocysteinemia,” Bioscience, Biotechnology, and Biochemistry, vol. 79, no. 11, pp. 1884–1889, 2015. View at: Publisher Site | Google Scholar
  79. C. Ramachandran, G. Portalatin, K.-W. Quirin, E. Escalon, Z. Khatib, and S. J. Melnick, “Inhibition of AKT signaling by supercritical CO2 extract of mango ginger (Curcuma amada Roxb.) in human glioblastoma cells,” Journal of Complementary and Integrative Medicine, vol. 12, no. 4, pp. 307–315, 2015. View at: Publisher Site | Google Scholar
  80. C. Barthomeuf, S. Lamy, M. Blanchette, D. Boivin, D. Gingras, and R. Béliveau, “Inhibition of sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial cell chemotaxis by red grape skin polyphenols correlates with a decrease in early platelet-activating factor synthesis,” Free Radical Biology & Medicine, vol. 40, no. 4, pp. 581–590, 2006. View at: Publisher Site | Google Scholar
  81. M. W. Roomi, T. Kalinovsky, A. Niedzwiecki, and M. Rath, “Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines,” International Journal of Oncology, vol. 45, no. 2, pp. 887–894, 2014. View at: Publisher Site | Google Scholar
  82. M. W. Roomi, J. C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki, “Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines,” Oncology Reports, vol. 24, no. 3, pp. 747–757, 2010. View at: Publisher Site | Google Scholar
  83. W.-T. Chiu, S.-C. Shen, J.-M. Chow, C.-W. Lin, L.-T. Shia, and Y.-C. Chen, “Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE2 activation,” Neurobiology of Disease, vol. 37, no. 1, pp. 118–129, 2010. View at: Publisher Site | Google Scholar
  84. C.-W. Kang, M.-S. Park, N.-H. Kim et al., “Hexane extract from Sargassum serratifolium inhibits the cell proliferation and metastatic ability of human glioblastoma U87MG cells,” Oncology Reports, vol. 34, no. 5, pp. 2602–2608, 2015. View at: Publisher Site | Google Scholar
  85. Y.-C. Lin, J.-C. Lin, C.-M. Hung et al., “Osthole inhibits insulin-like growth factor-1-induced epithelial to mesenchymal transition via the inhibition of PI3K/Akt signaling pathway in human brain cancer cells,” Journal of Agricultural and Food Chemistry, vol. 62, no. 22, pp. 5061–5071, 2014. View at: Publisher Site | Google Scholar
  86. Y. Jiao, H. Li, Y. Liu et al., “Resveratrol inhibits the invasion of glioblastoma-initiating cells via down-regulation of the PI3K/Akt/NF-κB signaling pathway,” Nutrients, vol. 7, no. 6, pp. 4383–4402, 2015. View at: Publisher Site | Google Scholar
  87. J. Liu, C.-B. Qu, Y.-X. Xue, Z. Li, P. Wang, and Y.-H. Liu, “MIR-143 enhances the antitumor activity of shikonin by targeting BAG3 expression in human glioblastoma stem cells,” Biochemical and Biophysical Research Communications, vol. 468, no. 1-2, pp. 105–112, 2015. View at: Publisher Site | Google Scholar
  88. B. Tunca, G. Tezcan, G. Cecener et al., “Olea europaea leaf extract alters microRNA expression in human glioblastoma cells,” Journal of Cancer Research and Clinical Oncology, vol. 138, no. 11, pp. 1831–1844, 2012. View at: Publisher Site | Google Scholar
  89. H. Wu, Q. Liu, T. Cai, Y.-D. Chen, and Z.-F. Wang, “Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma,” Molecular Medicine Reports, vol. 12, no. 4, pp. 5461–5466, 2015. View at: Publisher Site | Google Scholar
  90. V. Kuete, P. Y. Ango, and S. O. Yeboah, “Cytotoxicity of four Aframomum species (A. arundinaceum, A. alboviolaceum, A. kayserianum and A. polyanthum) towards multi-factorial drug resistant cancer cell lines,” BMC Complementary and Alternative Medicine, vol. 14, no. 1, p. 340, 2014. View at: Publisher Site | Google Scholar
  91. V. Kuete, L. P. Sandjo, J. L. N. Ouete, H. Fouotsa, B. Wiench, and T. Efferth, “Cytotoxicity and modes of action of three naturally occurring xanthones (8-hydroxycudraxanthone G, morusignin i and cudraxanthone I) against sensitive and multidrug-resistant cancer cell lines,” Phytomedicine, vol. 21, no. 3, pp. 315–322, 2014. View at: Publisher Site | Google Scholar
  92. C. Oehler, K. Frei, E. J. Rushing et al., “Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial,” Oncology (Switzerland), vol. 83, no. 1, pp. 1–9, 2012. View at: Publisher Site | Google Scholar
  93. K. L. Black, J. D. Ciacci, M. Ammirati, M. T. Selch, and D. P. Becker, “Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma,” Journal of Clinical Oncology, vol. 11, no. 9, pp. 1746–1750, 1993. View at: Publisher Site | Google Scholar
  94. V. Devi, N. Jain, and K. Valli, “Importance of novel drug delivery systems in herbal medicines,” Pharmacognosy Reviews, vol. 4, no. 7, pp. 27–31, 2010. View at: Publisher Site | Google Scholar
  95. O. Keunen, M. Johansson, A. Oudin et al., “Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 108, no. 9, pp. 3749–3754, 2011. View at: Publisher Site | Google Scholar

Copyright © 2017 Moon Nyeo Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles